Suzhou Zhihui Biopharmaceutical Technology

Suzhou Zhihui Biopharmaceutical Technology is a Chinese biotechnology company focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases. The company specializes in targeting G protein-coupled receptors (GPCRs), particularly those involved in glucose homeostasis and energy metabolism, such as GLP-1, GIP, and Glucagon receptors. Their primary goal is to develop oral alternatives to injectable peptide therapies for conditions like type 2 diabetes and obesity. Based in the Suzhou Industrial Park, the firm leverages advanced medicinal chemistry and structural biology to advance its early-stage pipeline.